中国临床药学杂志

目的探讨四季抗病毒合剂联合磷酸奥司他韦颗粒治疗儿童上呼吸道感染的临床疗效。方法选取2019年3月至2020年2月收治的124例上呼吸道感染患儿,按随机数字表法分为对照组(n=62)与研究组(n=62)。对照组患儿予磷酸奥司他韦颗粒,按患儿体质量给药(体质量<15、15～23、23～40、> 40 kg患儿,剂量依次为30、45、60、75 mg),po,bid;研究组联合四季抗病毒合剂治疗,剂量为2～5岁患儿每次口服5 m L,5～12岁患儿每次7.5 m L,po,tid。比较2组临床症状消失时间,以及治疗前后白介素-1β(IL-1β)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平,评估2组临床治疗效果与安全性。结果研究组临床总有效率显著高于对照组(93.55%vs 83.87%,P <0.05),患儿发热、流鼻涕、咽痛及咳痰等临床症状消失时间均显著短于对照组(P <0.05)。2组患儿治疗后体内IL-1β、IL-6和TNF-α等炎性指标水平均显著低于治疗前(P <0.01),且研究组患儿上述炎性指标均显著低于对照组(P <0.01)。2组均未见不良反应发生。结论四季抗病毒合剂联合磷酸奥司他韦颗粒治疗儿童上呼吸道感染临床疗效及安全性均较佳,不仅能有效减轻患儿发热、流鼻涕、咽痛及咳痰等临床症状,同时还能减轻炎性反应,促进患儿病情好转。

AIM To explore the clinical effect of Siji antiviral mixture combined with oseltamivir phosphate granules on children with upper respiratory tract infection. METHODS A total of 124 children with upper respiratory tract infection admitted from March 2019 to February 2020 were randomly divided into control group(n=62) and study group(n=62). The children in the control group were treated with oseltamivir phosphate granules according to body weight(the body weight was < 15, 15-23, 23-40, > 40 kg, the dosage was 30, 45, 60 and 75 mg), po, bid, while the children in the study group were treated with oseltamivir phosphate granules combined with Siji antiviral mixture, with the dosage of 5 mL for 2-5 years old and 7.5 mL for 5-12 years old, po, tid. The clinical treatment effect and economic cost between 2 groups were compared. The disappearance time of clinical symptoms between 2 groups were compared. Before and after treatment, IL-1β, IL-6 and TNF-α were compared between 2 groups. RESULTS The total clinical effective rate in the study group was significantly higher than that in the control group(93.55% vs 83.87%, P < 0.05). The disappearance time of fever, runny nose, sore throat and expectoration in the study group were significantly lower than those in the control group(P < 0.05). After treatment, the inflammatory indexes of IL-1β, IL-6 and TNF-α in 2 groups were significantly lower than those before treatment(P < 0.01), and the above inflammatory indexes in the study group were significantly lower than those in the control group(P < 0.01). No adverse drug reactions were found in 2 groups(P < 0.05). CONCLUSION Siji antiviral mixture combined with oseltamivir phosphate granules has better clinical efficacy and safety in the treatment of children's upper respiratory tract infection. It can not only effectively reduce the children's fever, runny nose, sore throat, expectoration and other clinical symptoms, but also reduce the inflammatory response, and promote the improvement of children's condition.